| Heart disease and stroke statistics—2012 update: a report from the American Heart Association Writing Group Members, VL Roger, AS Go, DM Lloyd-Jones, EJ Benjamin, ... Circulation 125 (1), e2-e220, 2012 | 31043* | 2012 |
| Heart disease and stroke statistics—2016 update: a report from the American Heart Association D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ... circulation 133 (4), e38-e360, 2016 | 29079* | 2016 |
| Prasugrel versus clopidogrel in patients with acute coronary syndromes SD Wiviott, E Braunwald, CH McCabe, G Montalescot, W Ruzyllo, ... New England Journal of Medicine 357 (20), 2001-2015, 2007 | 8144 | 2007 |
| Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium R Mehran, SV Rao, DL Bhatt, CM Gibson, A Caixeta, J Eikelboom, S Kaul, ... Circulation 123 (23), 2736-2747, 2011 | 4199 | 2011 |
| COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review B Bikdeli, MV Madhavan, D Jimenez, T Chuich, I Dreyfus, E Driggin, ... Journal of the American college of cardiology 75 (23), 2950-2973, 2020 | 3335 | 2020 |
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation MS Sabatine, CP Cannon, CM Gibson, JL López-Sendón, G Montalescot, ... New England Journal of Medicine 352 (12), 1179-1189, 2005 | 2907 | 2005 |
| TIMI frame count: a quantitative method of assessing coronary artery flow CM Gibson, CP Cannon, WL Daley, JT Dodge Jr, B Alexander, SJ Marble, ... Circulation 93 (5), 879-888, 1996 | 2639 | 1996 |
| Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban CP Cannon, WS Weintraub, LA Demopoulos, R Vicari, MJ Frey, N Lakkis, ... New England Journal of Medicine 344 (25), 1879-1887, 2001 | 2561 | 2001 |
| Rivaroxaban in patients with a recent acute coronary syndrome JL Mega, E Braunwald, SD Wiviott, JP Bassand, DL Bhatt, C Bode, ... New England Journal of Medicine 366 (1), 9-19, 2012 | 2436 | 2012 |
| Prevention of bleeding in patients with atrial fibrillation undergoing PCI CM Gibson, R Mehran, C Bode, J Halperin, FW Verheugt, P Wildgoose, ... New England Journal of Medicine 375 (25), 2423-2434, 2016 | 1636 | 2016 |
| Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction CP Cannon, CM Gibson, CT Lambrew, DA Shoultz, D Levy, WJ French, ... Jama 283 (22), 2941-2947, 2000 | 1612 | 2000 |
| Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised … G Montalescot, SD Wiviott, E Braunwald, SA Murphy, CM Gibson, ... The Lancet 373 (9665), 723-731, 2009 | 1384 | 2009 |
| The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis TD Henry, BH Annex, GR McKendall, MA Azrin, JJ Lopez, FJ Giordano, ... Circulation 107 (10), 1359-1365, 2003 | 1362 | 2003 |
| Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs CM Gibson, CP Cannon, SA Murphy, KA Ryan, R Mesley, SJ Marble, ... Circulation 101 (2), 125-130, 2000 | 1226 | 2000 |
| Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide MS Sabatine, DA Morrow, JA de Lemos, CM Gibson, SA Murphy, N Rifai, ... Circulation 105 (15), 1760-1763, 2002 | 1043 | 2002 |
| Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial EM Antman, RP Giugliano, CM Gibson, CH McCabe, P Coussement, ... Circulation 99 (21), 2720-2732, 1999 | 995 | 1999 |
| Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study MS Sabatine, CP Cannon, CM Gibson, JL López-Sendón, G Montalescot, ... Jama 294 (10), 1224-1232, 2005 | 964 | 2005 |
| Andexanet alfa for acute major bleeding associated with factor Xa inhibitors SJ Connolly, TJ Milling Jr, JW Eikelboom, CM Gibson, JT Curnutte, A Gold, ... New England Journal of Medicine 375 (12), 1131-1141, 2016 | 927 | 2016 |
| Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy RH Chan, BJ Maron, I Olivotto, MJ Pencina, GE Assenza, T Haas, ... Circulation 130 (6), 484-495, 2014 | 922 | 2014 |
| Effect of platelet inhibition with cangrelor during PCI on ischemic events DL Bhatt, GW Stone, KW Mahaffey, CM Gibson, PG Steg, CW Hamm, ... New England Journal of Medicine 368 (14), 1303-1313, 2013 | 893 | 2013 |
Christopher P. CannonProfessor of Medicine, Harvard Medical School, Brigham and Women's HospitalVerified email at bwh.harvard.edu
